Total Funding
67
58
Total FundingPost-IPO Equity raised
Growth Score
-23 pts
Heat Score
15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
31716
Hemostemix is a public clinical-stage biotechnology company.
- Croom Lawrence: Chief Commercial Officer
- Richard T. Groome: Special Advisor to The CEO
About the Company
Hemostemix a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial
for the treatment of critical limb ischemia. It is also developing various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors.
